Study to Evaluate the Safety and Efficacy of JVS-100 Administered to Adults With Ischemic Heart Failure.

PHASE2UnknownINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

October 31, 2014

Study Completion Date

November 30, 2014

Conditions
Ischemic Heart Failure
Interventions
BIOLOGICAL

JVS-100 15 mg dose Injection

Intramyocardial Injection

BIOLOGICAL

Placebo Injection

Intramyocardial Injection

BIOLOGICAL

JVS-100 30 mg dose injection

Intramyocardial Injection

Trial Locations (16)

10032

Columbia University Medical Center, New York

10476

Montefiore Medical Center, New York

19104

University of Pennsylvania Health System, Philadelphia

21287

Johns Hopkins University, Baltimore

32603

University of Florida, Gainesville

33613

Pepin Heart Institute, Tampa

35211

Cardiology PC, Birmingham

44309

Summa Health System, Akron

45238

The Lindner Center at the Christ Hospital, Cincinnati

48601

Michigan Cardiovascular Institute, Saginaw

49503

Spectrum Health, Grand Rapids

50026

Iowa Heart Center, Des Moines

55407

Minneapolis Heart Institute, Minneapolis

63110

Washington University in St. Louis, St Louis

75226

Baylor Healthcare, Dallas

84132

University of Utah, Salt Lake City

Sponsors
All Listed Sponsors
lead

Juventas Therapeutics, Inc.

INDUSTRY